Menu

FLAGSHIP CASE STUDY

Pharmaceutical Receivables: Government Procurement and Trade-Channel Recovery

Published and reviewed: 2 October 2026

An Indian pharmaceutical business selling to central and state procurement bodies, government and private hospitals, and a national trade channel. 65% of trade debtors sat beyond 180 days. 70% of the outstanding was collected — and 18% turned out to be commercial dispute nobody had ever quantified.

70%Of the outstanding collected within the assignment
18%Commercial and service dispute, not collectable
65%Of trade debtors beyond 180 days at the outset
7%Absconded and untraceable
5%Forecast into the following months

The argument

A government invoice fails for want of a document. A trade invoice fails for want of an agreement. The same collections process cannot recover both, and most pharmaceutical companies run only one.

01

Executive summary

An Indian pharmaceutical business sells through four distinct routes: central and state government procurement bodies, government hospitals, private hospitals, and a national network of dealers and distributors. Overdue debtors kept growing despite sustained sales effort, and 65% of trade channel debtors sat beyond 180 days at the point of engagement.

  1. 70% of the outstanding was collected within the assignment period. On a book of this age and composition, that is an unusually high conversion — and the reason is that most of it failed for documentary rather than commercial reasons.
  2. 18% was commercial, service or process dispute and was not collectable. Quantified, evidenced and reported back so that internal processes could be corrected rather than the same claims recurring.
  3. 7% could not be collected because the dealer had absconded and could not be located. 5% was forecast into the following months.
  4. The ledger contains two books that fail for opposite reasons. Institutional invoices fail on documentation — a missing goods receipt, an unsigned approval, a portal upload never made. Trade invoices fail on commercial disagreement — short-expiry stock, unhonoured schemes, dumped material.
  5. Government recovery is an evidence exercise, not a persuasion exercise. Supplies to multiple locations without collected receipt certificates, LD deductions for delayed supply, expiry norms unmet, signatures not obtained, approvals pending across procurement, user and accounting departments — each is a document, and each has an owner. Receipt, approval and accounting are the buyer's own payables stages; GGA tracked each one.
  6. Trade recovery required auditing the dispute before negotiating it. Expired stock was verified at batch level against the sales register to confirm it had genuinely been sold to that dealer, and claim values were tested against promised price versus invoiced price before any settlement was discussed.
04

Recovering from the trade channel

The trade half behaves like any credit-funded distribution channel, with one industry-specific complication: the product expires.

Dealers do not fund supplier invoices from their own capital. They pay once they have recovered from the market beneath them. If their own collections slip, the supplier's slip identically — which makes the real credit exposure the retail pharmacy market rather than the distributor.

Why the invoices had not been paid

  • The dealer had stopped buying, so nobody had a live reason to call and the balance aged unattended.
  • Short-expiry stock had been supplied, leaving unsold expired inventory and a discount claim for having accepted it in the first place. This is the dispute unique to pharmaceuticals, and it is legitimate more often than not.
  • Verbal credit terms far beyond the invoice — dealers reporting they were told to pay once the material sold, with 180 days understood.
  • Excess or unordered material dumped at period end with an undertaking to help liquidate it that was never honoured.
  • Schemes and discounts announced and never passed, against which the dealer withheld payment.
  • No surviving counterparty — shuttered shops, deceased proprietors, dissolved partnerships where no partner would accept the old dues.

What recovered them

The sequence mattered more than the effort. Each disputed claim was documented with supporting evidence before any negotiation began. Claim values were tested against promised price versus sales register value, so the conversation started from a number both sides could see.

Expired stock was audited at batch level with the customer's supply chain and finance teams, and validated against the sales register to confirm the material had genuinely been sold to that dealer in the first place. A meaningful share of expiry claims do not survive that test; the ones that do are settled quickly because they are unarguable.

Only then was a receivable value agreed and a payment plan negotiated, with adherence monitored rather than assumed.

Auditing the dispute before negotiating it is what separates a settlement from a discount. A dealer presenting an unverified expiry claim is asking for a write-off. A dealer whose claim has been batch-validated is presenting a fact, and the remaining balance becomes collectable.
05

What the assignment produced

Outcome on the outstanding book
OutcomeShareWhat it represents
Collected70%Cash received within the assignment period, across institutional and trade.
Commercial, service and process dispute18%Quantified, evidenced and reported to management as not collectable, with the underlying process defects identified.
Absconded and untraceable7%Dealer could not be located. A provisioning decision, not a collections case.
Forecast to following months5%Live cases with an agreed path and expected timing.

70% is high for a book of this age, and the composition explains it. A large share of the outstanding was institutional — where payment intent is not in question and the obstacle is documentary. Once the certificate is retrieved, the portal upload made and the signature obtained, the money moves. That is laborious work with a high conversion rate, and it is the opposite of the trade channel profile in the same ledger.

The 18% was reported as a management finding rather than a collections failure. Each dispute carried an evidenced value and a cause — short-expiry supply, unhonoured scheme, dumped stock, service issue. Fed back into commercial practice, those causes stop recurring; left unreported, they rebuild the same book within two years.

06

What this says for a pharmaceutical business

Six conclusions, in order of how much cash they move.

  1. Split the ledger before you resource the collections. Institutional and trade fail for opposite reasons and respond to opposite interventions. Running one process across both means over-servicing the easy half and under-servicing the difficult one.
  2. Treat institutional recovery as document logistics. The highest-yield activity on that half of the book is physically collecting receipt certificates from despatch locations — not calling the finance department that cannot pay an invoice it has never received.
  3. Audit expiry claims at batch level before conceding them. Validate against the sales register that the material was sold to that dealer. Claims that fail the test disappear; claims that survive settle fast because they become unarguable.
  4. Reclaim your EMDs and bank guarantees. Money lodged against concluded tenders sits unclaimed because the paperwork was not retained. It is recoverable with partial information and regional presence, and almost nobody asks for it.
  5. Do not supply short-expiry stock. It converts directly into an expiry claim, a discount demand and a disputed balance — and it contaminates every subsequent invoice to that dealer.
  6. Load the portal while the product is still in date. On this book, invoices could not be uploaded at all because product expiry had passed and the system refused them. That is money made structurally unreachable by a filing delay.

Evidence boundary

This is historical evidence from one GGA engagement. It explains the starting position, operating mechanism and measured outcome on the stated denominator. It is not a universal benchmark, forecast or recovery guarantee for another portfolio.

Percentages from different denominators or measurement dates are not combined.

Email GGA gg@ggaindia.co.in